Caris Life Sciences

Historical price data

Caris Life Sciences, founded in 2008, is a precision oncology pioneer with a mission to improve the human condition through molecular science and artificial intelligence. The company has achieved significant scale, having processed over 1 million cases and built one of the world's largest multimodal databases of matched molecular and clinical outcomes data. Its strategy revolves around serving the full cancer care continuum—from detection to therapy selection and monitoring—for patients and physicians, while also providing critical translational medicine and real-world evidence services to biopharma companies to accelerate drug development.

Molecular Intelligence® platform combining comprehensive multimodal molecular profiling (Whole Exome, Whole Transcriptome, Proteomics) with a massive, matched molecular-clinical database and sophisticated AI/ML algorithms to generate predictive insights for cancer care.

Caris competes with Foundation Medicine (Roche) in tissue-based comprehensive profiling, Guardant Health in liquid biopsy, and Tempus in AI-driven oncology data. Its differentiation lies in its multimodal data integration (DNA+RNA+protein), proprietary cNAS liquid biopsy tech, and one of the world's largest matched molecular-clinical databases.